Human Vaccine Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Nov 2023 Pages: 166 SKU: IRTNTR70325

Human Vaccine Market 2024-2028

The Human Vaccine Market size is estimated to grow by USD 29.1 billion at a CAGR of 9.49% between 2023 and 2028. 

There has been a rise in public immunization programs funded by the governments of various countries which is significantly contributing to the market growth. For example, UIP was launched by the Government of India to provide vaccines against tuberculosis, polio, and other diseases for all Indian children Moreover, UIP provided vaccines that included BCG for TB, DPT for diphtheria, pertussis, and tetanus, oral polio vaccine (OPV), and vaccines for measles. Hence, such factors are positively impacting the market.

Technavio has segmented the market into Route Of Administration, End-user, and Geography

  • The route of administration segment is classified into intramuscular, subcutaneous, and oral
  • The end-user segment is classified into pediatrics and adults
  • The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Human Vaccine Market During the Forecast Period?

To learn more about this report, Request Free Sample

Human Vaccine Market Segmentation by Route Of Administration, End-user and Geography Analysis

Route Of Administration Analysis

Intramuscular

The intramuscular segment is estimated to witness significant growth during the forecast period. One of the main factors for the growth of this segment is the benefits of intramuscular administration. In addition, it is efficient and safe in inducing an immune response compared with the oral ROA. Furthermore, oral vaccination is associated with some risk factors, such as a rich microbiome and enteropathy.

Get a glance at the market contribution of various segments Download PDF Sample

The intramuscular segment was the largest segment and was valued at USD 16.37 billion in 2018. Moreover,  most of the vaccines are delivered parenterally, mainly intramuscularly, in infants and children. In addition, several pipeline vaccine products are being evaluated in the intramuscular ROA because of their advantages over the oral ROA. Furthermore, the market has witnessed the development and approval of an intramuscular vaccine for COVID-19, which is positively impacting the market. For instance, the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, is an mRNA vaccine encoded with a P2 mutant spike protein and formulated as an RNA lipid nanoparticle of nucleoside-modified mRNA. BNT162b2 elicits a blunted innate immune sensor-activating capacity and thus augments antigen expression. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

End User Analysis

Pediatrics

The pediatric age group is of high significance in the global vaccine research market due to the sustained emphasis on the creation and delivery of vaccines for children. The health of children across the world has been greatly improved, and different infectious childhood diseases have been eradicated due to the pediatric vaccination programs carried out worldwide. The market environment for pediatric vaccinations is characterized by rising R&D spending, stringent regulatory standards, and rising demand for vaccines that are both safe and efficacious for children. For instance, vaccines against diseases such as measles, mumps, rubella (MMR) and diphtheria, tetanus, and pertussis (DTaP) are widely administered to children across the world and have been the subject of substantial research globally. Such factors will drive the growth of the global human vaccine market during the forecast period.

Adults

In the global human vaccine market, vaccines targeted at the adult age group are experiencing tremendous expansion and development. A growing emphasis is being placed on creating vaccines that are specifically aimed at adults, primarily due to the aging population and rising awareness of diseases that can be prevented by vaccination. In the adult vaccine industry, vaccines for influenza, pneumococcal disease, and shingles have become increasingly popular.  Further more as new vaccines are discovered, and vaccination rates increase globally, adult vaccine research is anticipated to continue growing and drive the growth of the global human vaccine market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. One of the main factors for the growth of the market in North America is due to the increasing number of immunization programs and the strong prevalence of infectious diseases such as influenza, hepatitis A, hepatitis B, HIV, measles, malaria, tuberculosis, and non-infectious diseases such as cancer. 

In addition, the prevalence of several infectious and non-infectious diseases has been increasing at a significant rate in the developed countries of the region. For example,  in the US, the prevalence of influenza rises every year in November and remains high for several weeks, from January to February each year. Furthermore, some of the prominent vaccine players in North America include  GlaxoSmithKline, Pfizer, Merck, and Johnson & Johnson. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Key Human Vaccine Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Astellas Pharma Inc: The company offers human vaccines such as Acam2000, BAT, BioThrax and many more.

  • AstraZeneca Plc
  • Bavarian Nordic AS
  • Bharat Biotech Ltd.
  • BioNTech SE
  • CanSino Biologics Inc.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Gradalis Inc.
  • Inovio Pharmaceuticals Inc.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Mitsubishi Chemical Group Corp.
  • Moderna Inc.
  • Novavax Inc.
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sanofi SA

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Human Vaccine Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Human Vaccine Market Drivers

One of the key factors driving the human vaccine market growth is the need for novel vaccines for chronic infections.  There is an increasing need for novel vaccines to prevent several emerging and re-emerging infectious diseases. As a result, government and non-government organizations worldwide are increasing the research on novel vaccines for various infections, including HIV, Staphylococcus aureus, C. difficile, influenza, and respiratory syncytial virus. In addition, with the use of new and traditional technologies, many vaccine candidates have been studied in clinical research.

Moreover, there are numerous vaccine targets, including Group A streptococcal meningitis, Chlamydia trachomatis, pneumococcal, universal influenza, and C. difficile across the world. In addition, funding for vaccine development comes from several organizations, such as Global Health and US Federal Funding for translational medicines. Hence, such factors are positively impacting the market. Therefore, it is expected to drive the market growth during the forecast period.

Significant Human Vaccine Market Trends

A key factor shaping the human vaccine market growth is the development in nano-particle vaccines. The emergence of various infectious and other diseases has become a  serious threat to the health of millions of people worldwide. In addition, some vaccines were developed by researchers from protein subunits and killed pathogens, whereas several vaccines were based on live attenuated organisms. However, these vaccines have the risk of regaining their pathogenicity under certain immunocompromised conditions.

Therefore, to overcome this challenge, the development of effective vaccines in combination with adequate delivery systems is important to obtain the desired humoral and cell-mediated immunity against specific diseases. Furthermore, over the years, the development of nanoparticle-based vaccines has been gaining traction for improving immunization strategies, vaccine efficacy, and targeted delivery to achieve desired immune responses. Hence, such factors are driving the market growth during the forecast period.

Major Human Vaccine Market Challenges

Concerns about the safety of vaccines are one of the key challenges hindering the human vaccine market growth. There are numerous risks associated with the vaccine such as the increased risk of certain diseases such as autism and the Guillain-Barre syndrome. In addition, studies by the CDC indicate that vaccination may not be related to these diseases.

Moreover, the common side effects of vaccination include injection site reactions, mild fever, fatigue, pain, and fainting. In addition, some vaccines may show serious effects. For example, the dengue vaccine has serious effects, including the occurrence of severe hemorrhagic dengue fever. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.

Buy Now Full Report

Key Human Vaccine Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Human Vaccine Market Customer Landscape

Segment Overview

The human vaccine market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Route of Administration Outlook
    • Intramuscular
    • Subcutaneous
    • Oral
  • End-user Outlook
    • Pediatrics
    • Adults
  • Geography Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World (ROW)
      • Australia
      • Argentina
      • Brazil

Human Vaccine Market Scope

Report Coverage

Details

Page number

166

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.49%

Market Growth 2024-2028

USD 29.1 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

8.56

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 39%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Group Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Serum Institute of India Pvt. Ltd., and Sanofi SA

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Human Vaccine Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the human vaccine market between 2024 and 2028
  • Precise estimation of the human vaccine market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of human vaccine market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global human vaccine market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global human vaccine market 2018 - 2022 ($ billion)
    • 4.2 Route of Administration Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Route of Administration Segment 2018 - 2022 ($ billion)
    • 4.3 End-user Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – End-user Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Route of Administration

    • 6.1 Market segments
      • Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
    • 6.2 Comparison by Route of Administration
      • Exhibit 32: Chart on Comparison by Route of Administration
      • Exhibit 33: Data Table on Comparison by Route of Administration
    • 6.3 Intramuscular - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Intramuscular - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Intramuscular - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Intramuscular - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Intramuscular - Year-over-year growth 2023-2028 (%)
    • 6.4 Subcutaneous - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Subcutaneous - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Subcutaneous - Year-over-year growth 2023-2028 (%)
    • 6.5 Oral - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Oral - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Oral - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Route of Administration
      • Exhibit 46: Market opportunity by Route of Administration ($ billion)
      • Exhibit 47: Data Table on Market opportunity by Route of Administration ($ billion)

    7 Market Segmentation by End-user

    • 7.1 Market segments
      • Exhibit 48: Chart on End-user - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on End-user - Market share 2023-2028 (%)
    • 7.2 Comparison by End-user
      • Exhibit 50: Chart on Comparison by End-user
      • Exhibit 51: Data Table on Comparison by End-user
    • 7.3 Pediatrics - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Pediatrics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Pediatrics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Pediatrics - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Pediatrics - Year-over-year growth 2023-2028 (%)
    • 7.4 Adults - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Adults - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Adults - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Adults - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Adults - Year-over-year growth 2023-2028 (%)
    • 7.5 Market opportunity by End-user
      • Exhibit 60: Market opportunity by End-user ($ billion)
      • Exhibit 61: Data Table on Market opportunity by End-user ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 63: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 65: Chart on Geographic comparison
      • Exhibit 66: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 China - Market size and forecast 2023-2028
      • Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.10 UK - Market size and forecast 2023-2028
      • Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.11 Canada - Market size and forecast 2023-2028
      • Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 103: Market opportunity by geography ($ billion)
      • Exhibit 104: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 105: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 107: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 108: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 109: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 110: Matrix on vendor position and classification
            • 12.3 Astellas Pharma Inc.
              • Exhibit 111: Astellas Pharma Inc. - Overview
              • Exhibit 112: Astellas Pharma Inc. - Product / Service
              • Exhibit 113: Astellas Pharma Inc. - Key news
              • Exhibit 114: Astellas Pharma Inc. - Key offerings
            • 12.4 AstraZeneca Plc
              • Exhibit 115: AstraZeneca Plc - Overview
              • Exhibit 116: AstraZeneca Plc - Product / Service
              • Exhibit 117: AstraZeneca Plc - Key news
              • Exhibit 118: AstraZeneca Plc - Key offerings
            • 12.5 Bavarian Nordic AS
              • Exhibit 119: Bavarian Nordic AS - Overview
              • Exhibit 120: Bavarian Nordic AS - Product / Service
              • Exhibit 121: Bavarian Nordic AS - Key offerings
            • 12.6 Bharat Biotech Ltd.
              • Exhibit 122: Bharat Biotech Ltd. - Overview
              • Exhibit 123: Bharat Biotech Ltd. - Product / Service
              • Exhibit 124: Bharat Biotech Ltd. - Key news
              • Exhibit 125: Bharat Biotech Ltd. - Key offerings
            • 12.7 CSL Ltd.
              • Exhibit 126: CSL Ltd. - Overview
              • Exhibit 127: CSL Ltd. - Business segments
              • Exhibit 128: CSL Ltd. - Key offerings
              • Exhibit 129: CSL Ltd. - Segment focus
            • 12.8 Daiichi Sankyo Co. Ltd.
              • Exhibit 130: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 131: Daiichi Sankyo Co. Ltd. - Product / Service
              • Exhibit 132: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 133: Daiichi Sankyo Co. Ltd. - Key offerings
            • 12.9 Emergent BioSolutions Inc.
              • Exhibit 134: Emergent BioSolutions Inc. - Overview
              • Exhibit 135: Emergent BioSolutions Inc. - Product / Service
              • Exhibit 136: Emergent BioSolutions Inc. - Key news
              • Exhibit 137: Emergent BioSolutions Inc. - Key offerings
            • 12.10 GlaxoSmithKline Plc
              • Exhibit 138: GlaxoSmithKline Plc - Overview
              • Exhibit 139: GlaxoSmithKline Plc - Business segments
              • Exhibit 140: GlaxoSmithKline Plc - Key news
              • Exhibit 141: GlaxoSmithKline Plc - Key offerings
              • Exhibit 142: GlaxoSmithKline Plc - Segment focus
            • 12.11 Inovio Pharmaceuticals Inc.
              • Exhibit 143: Inovio Pharmaceuticals Inc. - Overview
              • Exhibit 144: Inovio Pharmaceuticals Inc. - Product / Service
              • Exhibit 145: Inovio Pharmaceuticals Inc. - Key news
              • Exhibit 146: Inovio Pharmaceuticals Inc. - Key offerings
            • 12.12 Merck and Co. Inc.
              • Exhibit 147: Merck and Co. Inc. - Overview
              • Exhibit 148: Merck and Co. Inc. - Business segments
              • Exhibit 149: Merck and Co. Inc. - Key news
              • Exhibit 150: Merck and Co. Inc. - Key offerings
              • Exhibit 151: Merck and Co. Inc. - Segment focus
            • 12.13 Mitsubishi Chemical Group Corp.
              • Exhibit 152: Mitsubishi Chemical Group Corp. - Overview
              • Exhibit 153: Mitsubishi Chemical Group Corp. - Business segments
              • Exhibit 154: Mitsubishi Chemical Group Corp. - Key offerings
              • Exhibit 155: Mitsubishi Chemical Group Corp. - Segment focus
            • 12.14 Moderna Inc.
              • Exhibit 156: Moderna Inc. - Overview
              • Exhibit 157: Moderna Inc. - Product / Service
              • Exhibit 158: Moderna Inc. - Key offerings
            • 12.15 Pfizer Inc.
              • Exhibit 159: Pfizer Inc. - Overview
              • Exhibit 160: Pfizer Inc. - Product / Service
              • Exhibit 161: Pfizer Inc. - Key news
              • Exhibit 162: Pfizer Inc. - Key offerings
            • 12.16 Sanofi SA
              • Exhibit 163: Sanofi SA - Overview
              • Exhibit 164: Sanofi SA - Business segments
              • Exhibit 165: Sanofi SA - Key news
              • Exhibit 166: Sanofi SA - Key offerings
              • Exhibit 167: Sanofi SA - Segment focus
            • 12.17 Serum Institute of India Pvt. Ltd.
              • Exhibit 168: Serum Institute of India Pvt. Ltd. - Overview
              • Exhibit 169: Serum Institute of India Pvt. Ltd. - Product / Service
              • Exhibit 170: Serum Institute of India Pvt. Ltd. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 171: Inclusions checklist
                • Exhibit 172: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 173: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 174: Research methodology
                • Exhibit 175: Validation techniques employed for market sizing
                • Exhibit 176: Information sources
              • 13.5 List of abbreviations
                • Exhibit 177: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              human vaccine market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis